Literature DB >> 15044478

A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions.

Jérôme Deval1, Jean-Marc Navarro, Boulbaba Selmi, Jérôme Courcambeck, Joëlle Boretto, Philippe Halfon, Sarah Garrido-Urbani, Josephine Sire, Bruno Canard.   

Abstract

Mechanisms governing viral replicative capacity are poorly understood at the biochemical level. Human immunodeficiency virus, type 1 reverse transcriptase (HIV-1 RT) K65R or L74V substitutions confer viral resistance to 2',3'-dideoxyinosine (ddI) in vivo. The two substitutions never occur together, and L74V is frequently found in patients receiving ddI, while K65R is not. Here we show that recombinant viruses carrying K65R and K65R/L74V display the same resistance level to ddI (about 9.5-fold) relative to wild type. Consistent with this result, purified HIV-1 RT carrying K65R RT or K65R/L74V substitutions exhibits an 8-fold resistance to ddATP as judged by pre-steady state kinetics of incorporation of a single nucleotide into DNA. Resistance is due to a selective decrease of the catalytic rate constant k(pol): 22-fold (from 7.2 to 0.33 s(-1)) for K65R RT and 84-fold (from 7.2 to 0.086 s(-1)) for K65R/L74V RT. However, the K65R/L74V virus replication capacity is severely impaired relative to that of wild-type virus. This loss of viral fitness is correlated to a poor ability of K65R/L74V RT to use natural nucleotides relative to wild-type RT: 15% that of wild-type RT for dATP, 36% for dGTP, 50% for dTTP, and 25% for dCTP. The order of incorporation efficiency is wild-type RT > L74V RT > K65R RT > K65R/L74V RT. Processivity of DNA synthesis remains unaffected. These results explain why the two mutations do not combine in the clinic and might give a mechanism for a decreased viral fitness at the molecular level.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044478     DOI: 10.1074/jbc.M313534200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  K65R and K65A substitutions in HIV-1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies.

Authors:  Scott J Garforth; Robert A Domaoal; Chisanga Lwatula; Mark J Landau; Amanda J Meyer; Karen S Anderson; Vinayaka R Prasad
Journal:  J Mol Biol       Date:  2010-06-09       Impact factor: 5.469

2.  HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.

Authors:  Atsuko Hachiya; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Xiongying Tu; Krzysztof Palczewski; Yee Tsuey Ong; Zhe Li; Daniel T Griffin; Matthew M Schuckmann; Junko Tanuma; Shinichi Oka; Kamalendra Singh; Eiichi N Kodama; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2012-07-02       Impact factor: 5.157

3.  Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection.

Authors:  Scott J Garforth; Tae Woo Kim; Michael A Parniak; Eric T Kool; Vinayaka R Prasad
Journal:  J Mol Biol       Date:  2006-09-27       Impact factor: 5.469

4.  Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Peter K Quashie; Richard Bethell; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

5.  L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Hongmei Yang; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-03-27       Impact factor: 3.891

Review 6.  Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.

Authors:  Nicolas Sluis-Cremer; Mark A Wainberg; Raymond F Schinazi
Journal:  Future Microbiol       Date:  2015-10-30       Impact factor: 3.165

7.  Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Authors:  Jeffrey D Meteer; Raymond F Schinazi; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antiviral Res       Date:  2013-11-07       Impact factor: 5.970

8.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

9.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

10.  Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.

Authors:  Kalyan Das; Rajiv P Bandwar; Kirsten L White; Joy Y Feng; Stefan G Sarafianos; Steven Tuske; Xiongying Tu; Arthur D Clark; Paul L Boyer; Xiaorong Hou; Barbara L Gaffney; Roger A Jones; Michael D Miller; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.